Intravenous SRS-induced increases in tracheal mucous gel layer thickness: evidence for thromboxane involvement.
Intravenous (IV) slow reacting substance (SRS) challenge produces bronchoconstriction that can be reduced by cyclooxygenase inhibitors. This report shows that IV SRS challenge also produces significant increases in tracheal mucous gel thickness and that the increases are inhibited by pretreatment with indomethacin (4 mg/kg, PO) or imidazole (10 mg/kg, IV). The increase in gel thickness is preceded by increases in plasma thromboxane B2 (TXB2) levels and the inhibition of gel thickening by imidazole is paralleled by decreases in plasma TXB2 levels. Aerosolized SRS produces increases in tracheal mucous gel thickness which are not inhibited by either indomethacin or imidazole, but are significantly inhibited by FPL-55712. These findings indicate that SRS acts, not only directly to stimulate mucous secretion but also indirectly through an indomethacin and imidazole sensitive mechanism.
D000336:Aerosols; D000818:Animals; D004305:Dose-Response Relationship, Drug; D007275:Injections, Intravenous; D008297:Male; D009092:Mucous Membrane / Q000276:immunology / Q000502:physiology; D051381:Rats; D011919:Rats, Inbred Strains; D013189:SRS-A / Q000008:administration & dosage / Q000502:physiology*; D013929:Thromboxane B2 / Q000097:blood; D014132:Trachea / Q000276:immunology / Q000502:physiology*
D000336:Aerosols; D013189:SRS-A; D013929:Thromboxane B2